Skip to main content

Update on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancer

Gullick, William J. (2001) Update on HER-2 as a target for cancer therapy: alternative strategies for targeting the epidermal growth factor system in cancer. Breast Cancer Research, 3 (6). pp. 390-394. ISSN 1465-5411. (doi:10.1186/bcr328) (KAR id:3993)

Abstract

The epidermal growth factor (EGF) family of ligands and receptors interact to influence cell division, differentiation and motility. Much evidence supports their importance in causing and sustaining cell transformation in model systems and in human cancer. The exact mechanism by which this is achieved varies in different tumour types and from case to case. The EGF system is a target for new types of targeted chemotherapy. The choice of strategy will depend on the mechanism involved, however, and several approaches are under development or evaluation in clinical trials. Each will have a different spectrum of side effects and the potential for development of drug resistance.

Item Type: Article
DOI/Identification number: 10.1186/bcr328
Additional information: Free full-text article in PubMed Central and on Breast Cancer Research.
Uncontrolled keywords: cancer, chemotherapy, growth factor, growth factor receptor
Subjects: Q Science
R Medicine > RC Internal medicine > RC254 Neoplasms. Tumors. Oncology
Divisions: Divisions > Division of Natural Sciences > Biosciences
Depositing User: William Gullick
Date Deposited: 12 Jun 2008 11:09 UTC
Last Modified: 16 Nov 2021 09:42 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/3993 (The current URI for this page, for reference purposes)

University of Kent Author Information

Gullick, William J..

Creator's ORCID:
CReDIT Contributor Roles:
  • Depositors only (login required):

Total unique views for this document in KAR since July 2020. For more details click on the image.